The French Medicines Agency has set up new ways of working to ensure it is functioning well during the coronavirus pandemic, and is showing flexibility in its process for potential treatments.
The Agence Nationale de Sécurité du médicament et des Produits de Santé (ANSM – French Medicines Agency), said:
“As a public service and health security agency, we are organised to meet our essential missions, in particular to ensure the availability and security of health products and treatments for patients with COVID-19.
“The majority of ANSM agents are teleworking and some of us remain mobilised within the establishment in accordance with national recommendations, in order to preserve everyone’s health.
“To join us, we invite you to favour the electronic way.”
Read this announcement here.
In a further announcement, ANSM revealed accelerated procedures for clinical trials of treatments for COVID-19, hoping to speed up their development. Other trials may need to be delayed, however, and the Agency asks sponsors to “reassess the relevance of initiating or continuing a clinical trial”.
Read this announcement in full here.